UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed advanced or metastatic solid tumor incurable by surgery or other standard therapy
• Tumor site accessible by biopsy
• No brain metastasis
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• More than 3 months
• Hematopoietic:
• WBC at least 4,500/mm3
• Absolute neutrophil count at least 2,000/mm3
• Platelet count at least 150,000/mm3
• Hepatic:
• Bilirubin normal
• SGOT no greater than 2.5 times upper limit of normal
• Renal:
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No New York Heart Association class III or IV congestive heart failure
• Other:
• No peripheral neuropathy greater than grade I
• No history of allergic reactions to diuretics or antiemetics (e.g., 5-HT3 antagonists) that would preclude study
• No other uncontrolled illness that would preclude study, including intolerance to vigorous hydration
• No medical, social, or psychological factors that would preclude study
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
• No greater than 2 prior chemotherapy regimens
• Prior cisplatin allowed if cumulative dose no greater than 400 mg/m2
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• No concurrent radiotherapy
• Surgery:
• See Disease Characteristics
• Recovered from any prior surgery
• Other:
• At least 30 days since prior investigational drugs
• No other concurrent investigational drugs
• No other concurrent anticancer agents